# Evaluate the Safety and Feasibility of Same-Day Bilateral Epithelium-On Corneal Cross-Linking for Keratoconus

> **NCT07629557** · PHASE4 · RECRUITING · sponsor: **Glaukos Corporation** · enrollment: 15 (estimated)

## Conditions studied

- Keratoconus

## Interventions

- **DRUG:** Riboflavin Ophthalmic Solutions
- **DEVICE:** UV-A Irradiation System

## Key facts

- **NCT ID:** NCT07629557
- **Lead sponsor:** Glaukos Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-05-11
- **Primary completion:** 2027-09
- **Final completion:** 2027-09
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07629557

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07629557, "Evaluate the Safety and Feasibility of Same-Day Bilateral Epithelium-On Corneal Cross-Linking for Keratoconus". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07629557. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*